Anumana wins FDA breakthrough nod for AI algorithm that detects pulmonary hypertension
Related Articles
Anumana’s AI tool for pulmonary hypertension gets FDA breakthrough status
Medical Device Network: Anumana has received US Food and Drug Administration (FDA) Breakthrough Device Designation for its artificial intelligence (AI)-enhanced, electrocardiogram (ECG)-based Pulmonary Hypertension (PH) Early Detection Algorithm. The accurate,…May 24, 2022
Anumana’s AI-Driven Low Ejection Fraction ECG-AI Technology Recognized in CMS 2025 OPPS Final Rule, Expanding Access to Advanced Cardiovascular Care
Company’s ECG-AI algorithm enables earlier heart failure detectionNovember 05, 2024
Anumana Entered into a Multi-Year Strategic Collaboration with Novartis to Develop ECG AI Algorithms for the Detection of Heart Disease
PharmaShots: The companies collaborated to develop & deliver new medical device software i.e., ECG AI algorithms for earlier detection of heart disease. The AI will screen for atherosclerotic CV disease…July 13, 2022
How Doctors Use AI to Help Diagnose Patients
Wall Street Journal: At Mayo cardiology, an AI tool has helped doctors diagnose new cases of heart failure and cases of irregular heart rhythms, which are called atrial fibrillation, potentially…February 28, 2023